Compare CTRI & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRI | DYN |
|---|---|---|
| Founded | 1909 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2024 | 2020 |
| Metric | CTRI | DYN |
|---|---|---|
| Price | $29.93 | $19.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $29.88 | ★ $37.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.6M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,982,781,000.00 | N/A |
| Revenue This Year | $14.62 | N/A |
| Revenue Next Year | $8.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.10 | N/A |
| 52 Week Low | $19.04 | $8.25 |
| 52 Week High | $42.99 | $25.00 |
| Indicator | CTRI | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 58.02 |
| Support Level | $27.81 | $16.47 |
| Resistance Level | $31.98 | $19.54 |
| Average True Range (ATR) | 1.29 | 1.18 |
| MACD | 0.14 | 0.17 |
| Stochastic Oscillator | 41.35 | 71.08 |
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. Its reportable segments are: (i) U.S. Gas Utility Services (U.S. Gas); (ii) Canadian Utility Services (Canadian Operations); (iii) Union Electric Utility Services (Union Electric); and (iv) Non-Union Electric Utility Services (Non-Union Electric).
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.